MNOV

Medicinova

• TipRanks·09/30 02:01

  Major Investor Makes a Big Exit Move in Medicinova

• TipRanks·09/28 21:12

  MediciNova Extends Office Lease, Signals Long-Term Stability

• Benzinga·09/28 17:06

  12 Health Care Stocks Moving In Monday's Intraday Session

• Benzinga·09/28 15:10

  MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

• TipRanks·09/28 15:10

  Analysts Are Bullish on Top Healthcare Stocks: Medicinova (MNOV), AbbVie (ABBV)

• Benzinga·09/28 12:05

  12 Health Care Stocks Moving In Monday's Pre-Market Session

• Dow Jones·09/28 11:15

  MediciNova Stock Falls on Topline Results from Phase 2 Trial for Fatty Liver Disease Treatment

• NASDAQ·09/28 10:49

  MediciNova Reports Phase 2 MN-001 Data In T2DM-Associated NAFLD; Stock Plunges In Premarket

• Benzinga·09/28 10:15

  MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant

• TipRanks·09/28 10:15

  MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001

• TipRanks·09/25 18:45

  Buy Rating Reaffirmed on MediciNova as Advancing Pipeline and Upcoming Catalysts Support Unchanged $6 Price Target

• NASDAQ·09/24 14:32

  MNOV Stock In Focus As COMBAT-ALS Completes Double-Blind Phase; Results Due By Year-End

• TipRanks·09/24 14:05

  Analyst Reiterates Buy on Medicinova, Maintaining $10 Price Target Amid Advancing ALS and Metabolic Disease Programs

• Benzinga·09/24 10:10

  MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis

• TipRanks·09/24 10:10

  MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166